trial

A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

NCTId NCT04742413
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Terminated
Enrollment 9 (actual)
Sponsored by Angelini Farmacéutica
Primary completion 2022-02-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
9 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2020-12-29
Primary completion
2022-02-15
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
—

Sponsors

Angelini FarmacéuticaLead Sponsor

Sites

10 total
Málaga, SpainPalma de Mallorca, SpainPalma de Mallorca, SpainLeón, SpainSalamanca, SpainZamora, SpainSantiago de Compostela, SpainVigo, SpainMadrid, SpainMadrid, Spain

Facts & assertions

4 sourced
Enrollment
9
Phase
NA
Primary Completion Date
2022-02-15
Status
TERMINATED
relationships
The graph out of here
lead_sponsor
Angelini Farmacéutica
company
indication
Schizophrenia
indication
Schizophrenia
indication